Efficacy Study of Ketamine for Postoperative Pain in Opioid Dependent Patients
This study is ongoing, but not recruiting participants.
Sponsor:
Brigham and Women's Hospital
Information provided by (Responsible Party):
Srdjan Nedeljkovic, Brigham and Women's Hospital
ClinicalTrials.gov Identifier:
NCT01591382
First received: May 1, 2012
Last updated: May 2, 2012
Last verified: May 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Patients who are dependent on opioids often have poor pain relief after major surgery. This study tests the hypothesis that adding intravenous ketamine to a postoperative regimen of intravenous opioids for postoperative pain will improve pain relief in this subset of patients.
| Condition | Intervention | Phase |
|---|---|---|
|
Postoperative Pain |
Drug: Ketamine Drug: Placebo |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Hydromorphone PCA or Hydromorphone PCA With Ketamine for Acute Postoperative Pain Relief in Opioid-Dependent Chronic Pain Patients |
Resource links provided by NLM:
Drug Information available for:
Hydromorphone hydrochloride
Hydromorphone
Ketamine hydrochloride
Ketamine
U.S. FDA Resources
Further study details as provided by Brigham and Women's Hospital:
Primary Outcome Measures:
- Pain relief [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 3 days ] [ Designated as safety issue: No ]Evaluate efficacy of ketamine for postop pain control in opioid-dependent patients who receive ketamine in addition to postop patient controlled analgesia with opioids
| Enrollment: | 64 |
| Study Start Date: | September 2008 |
| Estimated Study Completion Date: | June 2012 |
| Primary Completion Date: | June 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Ketamine
Ketamine is being compared to the use of placebo, in addition to intravenous opioids, for postop pain control in opioid dependent patients who undergo major surgery.
|
Drug: Ketamine
IV ketamine 0.2 mg/kg/hr for 24-48 hours postoperatively.
|
|
Placebo Comparator: Placebo
Patients who received placebo recieved an infusion of saline.
|
Drug: Placebo
Patients who received placebo were given saline infusions
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Chronic pain > 6 months
- Long term use of opioids
- Major surgery
Exclusion Criteria:
- Use of regional anesthetic techniques
- No need for IV PCA after surgery
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01591382
Locations
| United States, Massachusetts | |
| Brigham and Women's Hospital | |
| Boston, Massachusetts, United States, 02115 | |
Sponsors and Collaborators
Brigham and Women's Hospital
Investigators
| Principal Investigator: | Srdjan S Nedeljkovic, M.D. | Brigham and Women's Hospital |
More Information
No publications provided
| Responsible Party: | Srdjan Nedeljkovic, Staff, Pain Management Center, Brigham and Women's Hospital |
| ClinicalTrials.gov Identifier: | NCT01591382 History of Changes |
| Other Study ID Numbers: | 2008P001126 |
| Study First Received: | May 1, 2012 |
| Last Updated: | May 2, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Brigham and Women's Hospital:
|
Ketamine Postoperative pain Opioid dependent patients Acute pain control |
Additional relevant MeSH terms:
|
Pain, Postoperative Postoperative Complications Pathologic Processes Pain Signs and Symptoms Ketamine Hydromorphone Analgesics, Opioid Anesthetics, Dissociative Anesthetics, Intravenous Anesthetics, General Anesthetics Central Nervous System Depressants |
Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents Therapeutic Uses Excitatory Amino Acid Antagonists Excitatory Amino Acid Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Analgesics Sensory System Agents Peripheral Nervous System Agents Narcotics |
ClinicalTrials.gov processed this record on May 23, 2013